Brookline Capital Management Predicts CRSP FY2029 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Brookline Capital Management issued their FY2029 earnings estimates for CRISPR Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann expects that the company will earn $63.56 per share for the year. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.13) per share.

A number of other research firms have also weighed in on CRSP. Bank of America lowered their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. JMP Securities reiterated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Friday, December 20th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $78.38.

CRISPR Therapeutics Stock Performance

Shares of CRSP opened at $41.92 on Wednesday. CRISPR Therapeutics has a fifty-two week low of $38.20 and a fifty-two week high of $91.10. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -14.81 and a beta of 1.68. The firm has a 50 day moving average price of $46.63 and a 200-day moving average price of $48.94.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.42) by $0.41. The company had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the business earned ($1.41) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Baker BROS. Advisors LP increased its stake in CRISPR Therapeutics by 743.1% in the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock valued at $39,608,000 after purchasing an additional 743,075 shares during the last quarter. State Street Corp lifted its stake in shares of CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares during the period. Farallon Capital Management LLC acquired a new stake in shares of CRISPR Therapeutics during the 2nd quarter valued at approximately $28,625,000. Marshall Wace LLP purchased a new stake in CRISPR Therapeutics during the second quarter worth $10,078,000. Finally, Private Advisor Group LLC increased its stake in shares of CRISPR Therapeutics by 472.9% during the 2nd quarter. Private Advisor Group LLC now owns 77,627 shares of the company’s stock worth $4,193,000 after purchasing an additional 64,076 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. This represents a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,382 shares of company stock worth $2,744,179. 4.10% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.